Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service pacemaker, ICD & CRT implantation cases in Rhode Island: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (249 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 11 | 638 | 51% |
| 2020 | 14 | 614 | 53% |
| 2021 | 10 | 515 | 57% |
| 2022 | 9 | 434 | 60% |
| 2023 | 10 | 398 | 64% |
| 2024 | 9 | 460 | 66% |
| 2025 from claims | – | 464 375–545 | 67% |
| 2026 forecast | – | 482 378–606 | 66% |
| 2027 forecast | – | 487 361–644 | 66% |
| 2028 forecast | – | 492 348–679 | 67% |
| 2029 forecast | – | 496 337–712 | 67% |
| 2030 forecast | – | 501 328–743 | 67% |
Pacemaker, leadless, ICD, S-ICD, CRT, and generator replacements. Professional codes (what the surgeon bills): CPT 33206, 33207, 33208, 33274, 33249, 33270, 33262, 33263, 33264; the hospital bills MS-DRG 242, 243, 244, 226, 227, 275, 276, 277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Rhode Island; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 60% inpatient hospital, 40% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~480 | ~290 | ~190 |
| 2027 · ~490 | ~300 | ~190 |
| 2028 · ~490 | ~300 | ~190 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 39% (40% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 148 | 8,138−3%/yr | −3%/yr | 4.7 | 0% | 8,390 in 2030+0.5%/yr |
| Pennsylvania | 147 | 7,396−2.8%/yr | −2.8%/yr | 5.6 | 2% | 6,810 in 2030−1.4%/yr |
| New Jersey | 86 | 4,680−4.6%/yr | −4.6%/yr | 4.6 | 0% | 4,910 in 2030+0.8%/yr |
| Massachusetts | 90 | 4,351−1.6%/yr | −1.6%/yr | 4.7 | 0% | 4,910 in 2030+2%/yr |
| Connecticut | 40 | 1,648−4.1%/yr | −4.1%/yr | 5.2 | 0% | 1,830 in 2030+1.8%/yr |
| New Hampshire | 18 | 814−0.4%/yr | −0.4%/yr | 3.7 | 0% | 1,020 in 2030+3.7%/yr |
| Maine | 16 | 574−6.2%/yr | −6.2%/yr | 3.8 | 0% | 530 in 2030−1.4%/yr |
| Vermont | 10 | 413+2.4%/yr | +2.4%/yr | 3.7 | 0% | 710 in 2030+9.3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| EP ablation | 8 | 382+4.9%/yr | +4.9%/yr | 3.41.0× | 0% | 920 in 2030+16%/yr |
| LAA occlusion & loop recorders | 5 | 246−0.3%/yr | −0.3%/yr | 2.30.7× | 0% | 350 in 2030+6.1%/yr |
Pacemaker, ICD & CRT implantation in every state, and its device makers · Every procedure market in Rhode Island · Every state · Compare with New York
Abbott leads with 52% of company spending on these surgeons in 2025, +22 pts on 2024.
In 2025, 6 companies reported engagement with Rhode Island’s surgeons worth $35K in consulting, speaking, meals and travel tied to these products, about $3,874 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 339 clearances and approvals in the category, 3 recalled product lines (2 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.